Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
Read More

Vir Biotechnology Says Preclinical Data Highlight The Significant Antigenic Shift Of The Variant, Its Effect On Neutralizing Activity Of Monoclonal Antibodies, Convalescent Antibodies And Vaccine-Elicited Antibodies

Vir Biotechnology, Inc. (NASDAQ:VIR) today announced new preclinical data, published to the preprint server bioRxiv, demonstrating the impact of the significant antigenic shift of the new SARS-CoV-2 Omicron variant

VIR